je.st
news
Tag: patients
Air pollution may shorten survival of patients with lung cancer
2016-08-05 10:55:59| Green Car Congress
Tags: air
cancer
patients
survival
Mercks KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
2016-08-02 23:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
express
cell
approved
Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients
2016-06-30 14:30:58| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. and CHARLOTTE, N.C. Companies working alongside providers to develop solutions to serious public health needs KENILWORTH, N.J. and CHARLOTTE, N.C. -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis patients. Language: English read more
Tags: premier
prevent
patients
collaborate
Mercks KEYTRUDA (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
2016-06-16 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
cell
treatment
compared
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
2016-06-11 17:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »